Notice: file_put_contents(): Write of 4435 bytes failed with errno=28 No space left on device in /var/www/tg-me/post.php on line 50

Warning: file_put_contents(): Only 4096 of 8531 bytes written, possibly out of free disk space in /var/www/tg-me/post.php on line 50
Readhub | Telegram Webview: readhub_cn/254219 -
Telegram Group & Telegram Channel
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题



tg-me.com/readhub_cn/254219
Create:
Last Update:

智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/254219

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

China’s stock markets are some of the largest in the world, with total market capitalization reaching RMB 79 trillion (US$12.2 trillion) in 2020. China’s stock markets are seen as a crucial tool for driving economic growth, in particular for financing the country’s rapidly growing high-tech sectors.Although traditionally closed off to overseas investors, China’s financial markets have gradually been loosening restrictions over the past couple of decades. At the same time, reforms have sought to make it easier for Chinese companies to list on onshore stock exchanges, and new programs have been launched in attempts to lure some of China’s most coveted overseas-listed companies back to the country.

The seemingly negative pandemic effects and resource/product shortages are encouraging and allowing organizations to innovate and change.The news of cash-rich organizations getting ready for the post-Covid growth economy is a sign of more than capital spending plans. Cash provides a cushion for risk-taking and a tool for growth.

Readhub from fr


Telegram Readhub
FROM USA